不同剂量二甲双胍对老年2型糖尿病男性患者骨密度和骨代谢的影响

中国临床药理学与治疗学 ›› 2017, Vol. 22 ›› Issue (9): 1045-1049.

不同剂量二甲双胍对老年2型糖尿病男性患者骨密度和骨代谢的影响

史德军¹，刘义²

¹浙江省宁波市鄞州区第二医院，宁波 315100，浙江；²广东省天然药物研究与开发中心，广东医科大学，湛江 524025，广东

收稿日期:2016-12-28 修回日期:2017-02-23 出版日期:2017-09-26 发布日期:2017-09-30
作者简介:史德军，男，主治医师，本科，研究方向：骨代谢相关。 E-mail：shizuruyi@sina.com
基金资助:
广东省科技攻关项目（2011B06030032）

Effects of different doses of metformin on bone metabolism and bone mineral density in elderly male patients with type 2 diabetes

SHI Dejun ¹, LIU Yi²

¹The Second Hospital of Yinzhou, Ningbo 315100, Zhejiang, China; ²Guangdong Key Laboratory of Natural Medicine Research and Development, Guangdong Medical University, Zhanjiang 524025, Guangdong, China

Received:2016-12-28 Revised:2017-02-23 Online:2017-09-26 Published:2017-09-30

摘要/Abstract

摘要：

目的: 观察不同剂量二甲双胍对老年2型糖尿病患者骨密度和骨代谢的影响。方法: 未经治疗的老年2型糖尿病患者102例随机分为二甲双胍低剂量组（n=34）、二甲双胍中剂量组（n=34）和二甲双胍高剂量组（n=34）。3组分别给予：二甲双胍0.5 g，每日2次；二甲双胍0.5 g，每日3次；二甲双胍0.5 g，每日4次。3组均连续口服3个月。服药前和服药后1、3个月分别测定患者腰椎（L_2-4）与股骨颈（Neck）的骨密度（BMD）及血骨特异性碱性磷酸酶（BAP）、骨钙素（BGP）以及抗酒石酸酸性磷酸酶（TRACP）、护骨因子（OPG）、空腹血糖（FBG）和糖化血红蛋白水平（HbAlC）。结果: 3组治疗后FBG和HbAlC均明显降低，与治疗前比较差异有统计学意义（P<0.05），但3组间同期比较无统计学差异（P>0.05）。3组治疗前、后反映骨代谢的骨抑制指标TRACP和OPG无明显变化；反映骨转换与形成的指标BGP和BAP治疗后均升高，治疗前、后有统计学差异（P<0.05）。其中，二甲双胍高剂量组和中剂量组的BGP和BAP同期高于低剂量组，组间比较有统计学差异（P<0.05），而二甲双胍中剂量组和高剂量组的BGP和BAP同期无统计学差异（P>0.05）。3组治疗3个月后腰椎（L_2-4）与股骨颈（Neck）的BMD均明显增加，二甲双胍高剂量组和中剂量组分别与低剂量组比较有统计学差异，但二甲双胍高剂量组和中剂量组并没有明显差异。结论: 二甲双胍对老年性2型糖尿病患者在发挥降糖作用的同时，还能使患者BMD得到改善，该作用可能主要是通过促进骨形成实现的，且疗效有一定剂量相关性。

关键词: 二甲双胍, 2型糖尿病, 骨特异性碱性磷酸酶, 抗酒石酸酸性磷酸酶, 骨密度

Abstract:

AIM: To observe the effect of different doses of metformin on bone metabolism and bone mineral density in elderly male patients with type 2 diabetes. METHODS: 102 untreated elderly male patients with type 2 diabetes were randomly divided into 3 groups. 3 groups were given low doses of metformin group (1 g/d, n=34), medium doses of metformin group (1.5 g/d, n=34) and high doses of metformin group (2 g/d, n=34). Phase of treatment lasted for 3 months. The levels of bone mineral density (BMD) of lumbar L2-4 and the femoral neck, serum bone specific alkaline phosphatase (BAP), blood gla protein (BGP), Tartrate Resistant Acid Phosphatase (TRACP), osteoprotegrin (OPG), fasting blood glucose (FBG) and hemoglobin A1C (HbA1C) were measured before treatment, 1 month and 3 months after administration. RESULTS:The levels of FBP and HbA1C in 3 groups were decreased significantly after treatment (P<0.05), but there was not significant difference among 3 groups (P>0.05). The indicators of bone metabolism TRACP and OPG in 3 groups reflected no significant change before and after treatment (P>0.05); BGP and BAP which reflected indicators of bone turnover and formation were increased after treatment, there was significant difference among 3 groups (P<0.05). The levels of BGP and BAP in the medium doses and the high doses of metformin groups was higher than counterpart in low doses of metformin group (P<0.05), there were significant differences among groups. But the levels of BGP and BAP in the medium and high doses of metformin group were not obvious difference over the same period (P>0.05). After 12 weeks of treatment, the levels of BMD in 3 groups were increased, there was statistical significance among groups (P<0.05). The levels of BMD in the medium doses and the high doses of metformin groups was higher than counterpart in low doses of metformin group (P<0.05), there were significant differences among groups. But the levels of BMD in the medium and high doses of metformin group were not obvious difference over the same period (P>0.05). CONCLUSION:Metformin not only can regulate the levels of blood glucose in elderly male with type 2 diabetes, but also improve the BMD of patients. This effect may depend on promoting bone formation, and curative effects have a certain dose of relevance.

Key words: metformin, type 2 diabetes, bone specific alkaline phosphatase, tartrate resistant acid phosphatase, bone mineral density

中图分类号:

R587

史德军，刘义. 不同剂量二甲双胍对老年2型糖尿病男性患者骨密度和骨代谢的影响[J]. 中国临床药理学与治疗学, 2017, 22(9): 1045-1049.

SHI Dejun, LIU Yi. Effects of different doses of metformin on bone metabolism and bone mineral density in elderly male patients with type 2 diabetes[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(9): 1045-1049.

参考文献

［1］裴育，巴建明. 1型和2型糖尿病与骨质疏松症的关系［J］. 中华糖尿病杂志，2016，23(1): 12-14.
［2］王覃，陈德才. 糖尿病对骨质疏松症的影响及其机制［J］. 中华糖尿病杂志，2016，23(1): 5-7.
［3］Vestergard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes a meta-analysis ［J］. Osteoporo Int, 2007, 18(2): 427-444.
［4］Tolosa MJ, Chuguransky SR, Sedlinsky C, et al. Insulin-deficient diabetes-induced bone microarchitecture alteration are associated with a decrease in the osteogenic potential of bone marrow progenitor cells: preventive effects of metformin ［J］. Diabetes Res Clin Pract, 2013, 101(2): 177-186.
［5］Fontaine LJ, Chen C, Hunt N, et al. Type 2 diabetes and metformin influence on fracture healing in an experimental rat model ［J］. J Foot Ankle Surg, 2016, 55(5): 955-960.
［6］Zhen D, Chen Y, Tang X. Metformin reverses the deleterious effects of high glucose on osteobalst function ［J］. J Diabetes Complications,2010, 24(5): 334-344.
［7］Mai QG, Zhang ZM, Xu S, et al. Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblast and ovariectomized rats ［J］. J Cell Biochem, 2011, 112(10): 2902-2909.
［8］UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes ［J］. Lancet, 1998, 352(9131): 854-865.
［9］Garber AJ, Duncan TG, Goodman AM, et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial ［J］. Am J Med, 1997,103(6): 491-497.
［10］ Zinman B, Haffner SM, Herman WH, et al. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes ［J］. J Clin Endocrinol Metab, 2010, 95(1): 134-142.
［11］魏开惠，王振华. 二甲双胍对2型糖尿病患者骨代谢的影响［J］. 实用临床医药杂志，2015，19(13): 117-118.
［12］Kasai T, Bandow K, Suzuki H, et al. Osteoblast differentiation is functionally associated with decreased AMP kinase activity ［J］. J Cell Physiol, 2009, 221(3): 740-749.
［13］Shu A, Yin MT, Stein E, et al. Bone structure and turnover in type 2 diabetes mellitus ［J］. Osteoporos Int, 2012, 23(2): 635-641.
［14］Schurman L, Mccarthy AD, Sedlinsky C, et al. Metformin reverts deleterious effects of advanced glycation end-products (AGEs) on osteoblastic cells ［J］. Exp Clin Endocrinol Diabetes, 2008, 116(6): 333-340.
［15］Shah M, Kola B, Bataveljic A, et al. AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass ［J］. Bone, 2010, 47(2): 309-319.
［16］Jang WG, Kim EJ, Bae KN, et al. Metformin induces osteoblast differentiation via orphan nuclear receptor SHP-mediated transactivation of Runx2 ［J］. Bone, 2011, 48(4): 885-893.

[1]	马言, 田高鹏, 石兴文, 孙婷, 谢晶晶, 甄东户. 探讨T2DM人群中25（OH）D与代谢相关性脂肪肝的相关性[J]. 中国临床药理学与治疗学, 2023, 28(9): 1018-1026.
[2]	马仙康, 杨丽霞, 崔阳阳, 米登海. 当归多糖通过抑制GRP78、p-PERK、p-Eif2α表达改善糖尿病KK-Ay小鼠肝内质网应激[J]. 中国临床药理学与治疗学, 2023, 28(8): 926-936.
[3]	侯瑞英, 郭莉阁, 焦伟杰, 杜蕾, 吴桂月, 赵旭. 消渴舒方对2型糖尿病模型大鼠血清炎症因子的影响及其机制研究[J]. 中国临床药理学与治疗学, 2023, 28(4): 377-382.
[4]	赵世峰, 宋向明, 姚建平. 新型胰高血糖素样肽-1受体/葡萄糖依赖性促胰岛素多肽受体双重激动剂——Tirzepatide[J]. 中国临床药理学与治疗学, 2023, 28(2): 220-227.
[5]	王洁, 李龙, 陈凤, 刘胜菲. 二甲双胍干预肺纤维化发病机制的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 235-240.
[6]	赵阳婷, 陈重阳, 潘斌晶, 吕小羽, 刘靖芳. 三甲胺N-氧化物：骨质疏松治疗的潜在靶点[J]. 中国临床药理学与治疗学, 2023, 28(10): 1161-1167.
[7]	杜小雨, 李宇蒙, 吴惠珍, 邱博. 多格列艾汀治疗2型糖尿病的药理作用和临床评价[J]. 中国临床药理学与治疗学, 2023, 28(10): 1177-1183.
[8]	蔡静, 潘斌晶, 刘靖芳. 降糖药物与肌肉减少症关系的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(1): 101-108.
[9]	王歆, 刘维英, 武晨, 开锦军, 梁雪杰, 常瑛璇. 二甲双胍调节AMPK/SREBP-1通路及在临床中的应用进展[J]. 中国临床药理学与治疗学, 2022, 27(9): 1049-1054.
[10]	翟葳葳, 余巧玲, 刘平, 邱博, 吴惠珍. 非奈利酮在2型糖尿病合并慢性肾病治疗中的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(9): 1067-1074.
[11]	卢森林, 刘欣元, 王吉莉, 黄晓飞. 病毒载体介导的基因治疗在2型糖尿病中的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(7): 800-807.
[12]	王珍, 全海燕, 洪陈亮, 袁李佳龙, 秦旭平. 游泳运动通过促进自噬改善糖尿病小鼠肾功能的研究[J]. 中国临床药理学与治疗学, 2022, 27(6): 632-638.
[13]	曾晓凡, 许宜琪, 刘书, 吴茜, 李自保, 何俊俊, 金岳龙, 赵永莉, 何春玲, 高家林. 回顾性分析小剂量阿司匹林对2型糖尿病病人非致死性心梗和脑梗一级预防的作用[J]. 中国临床药理学与治疗学, 2022, 27(6): 665-671.
[14]	邵茜, 郁亚南, 黄钰涵, 王晓彤, 凌宏威, 吕冬梅, 王涛. 艾塞那肽降低2型糖尿病患者体重的预测因素研究[J]. 中国临床药理学与治疗学, 2022, 27(3): 287-294.
[15]	代红雨, 杨坤, 胡如春, 周红梅, 马佩敏, 郝倩. 0.25%罗哌卡因用于糖尿病患者坐骨神经阻滞的时效研究[J]. 中国临床药理学与治疗学, 2022, 27(11): 1278-1284.